Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 328

1.

Type II endometrial cancers with minimal, non-invasive residual disease on final pathology: What should we do next?

Mills KA, Lopez H, Sun L, Cripe JC, Litz T, Thaker PH, Powell MA, Mutch DG, Fuh KC.

Gynecol Oncol Rep. 2019 May 23;29:20-24. doi: 10.1016/j.gore.2019.05.007. eCollection 2019 Aug.

2.

Treatment Compliance as a Major Barrier to Optimal Cervical Cancer Treatment in Guatemala.

Zamorano AS, Barnoya J, Gharzouzi E, Chrisman Robbins C, Orozco E, Polo Guerra S, Mutch DG.

J Glob Oncol. 2019 May;5:1-5. doi: 10.1200/JGO.18.00243.

3.

Do gynecologic oncology patients with severely diminished renal function and urinary tract obstruction benefit from ureteral stenting or percutaneous nephrostomy?

Liang B, Lange SS, Massad LS, Dick R, Mills KA, Hagemann AR, McCourt CK, Thaker PH, Fuh KC, Mutch DG, Powell MA, Kuroki LM.

Gynecol Oncol Rep. 2019 Apr 24;28:136-140. doi: 10.1016/j.gore.2019.04.007. eCollection 2019 May.

4.

SOX11 hypermethylation as a tumor biomarker in endometrial cancer.

Shan T, Uyar DS, Wang LS, Mutch DG, Huang TH, Rader JS, Sheng X, Huang YW.

Biochimie. 2019 Jul;162:8-14. doi: 10.1016/j.biochi.2019.03.019. Epub 2019 Mar 29.

PMID:
30935961
5.

Dicer1 Phosphomimetic Promotes Tumor Progression and Dissemination.

Aryal NK, Pant V, Wasylishen AR, Rimel BJ, Baseler L, El-Naggar AK, Mutch DG, Goodfellow PJ, Arur S, Lozano G.

Cancer Res. 2019 May 15;79(10):2662-2668. doi: 10.1158/0008-5472.CAN-18-2460. Epub 2019 Mar 26.

PMID:
30914430
6.

Clinical outcomes after isolated pelvic failure in cervical cancer patients treated with definitive radiation.

Lin AJ, Ma S, Markovina S, Schwarz J, Mutch DG, Powell MA, Grigsby PW.

Gynecol Oncol. 2019 Jun;153(3):530-534. doi: 10.1016/j.ygyno.2019.03.104. Epub 2019 Mar 21.

PMID:
30905434
7.

p5RHH nanoparticle-mediated delivery of AXL siRNA inhibits metastasis of ovarian and uterine cancer cells in mouse xenografts.

Mills KA, Quinn JM, Roach ST, Palisoul M, Nguyen M, Noia H, Guo L, Fazal J, Mutch DG, Wickline SA, Pan H, Fuh KC.

Sci Rep. 2019 Mar 18;9(1):4762. doi: 10.1038/s41598-019-41122-3.

8.

Wound Complication Rates After Vulvar Excisions for Premalignant Lesions.

Mullen MM, Merfeld EC, Palisoul ML, Massad LS, Woolfolk C, Powell MA, Mutch DG, Thaker PH, Hagemann AR, Kuroki LM.

Obstet Gynecol. 2019 Apr;133(4):658-665. doi: 10.1097/AOG.0000000000003185.

PMID:
30870300
9.

Targeted metabolomic profiling of low and high grade serous epithelial ovarian cancer tissues: a pilot study.

Garg G, Yilmaz A, Kumar P, Turkoglu O, Mutch DG, Powell MA, Rosen B, Bahado-Singh RO, Graham SF.

Metabolomics. 2018 Nov 24;14(12):154. doi: 10.1007/s11306-018-1448-3.

PMID:
30830441
10.

GOG 8020/210: Risk stratification of lymph node metastasis, disease progression and survival using single nucleotide polymorphisms in endometrial cancer: An NRG oncology/gynecologic oncology group study.

Brooks RA, Tritchler DS, Darcy KM, Lankes HA, Salani R, Sperduto P, Guntupalli S, DiSilvestro P, Kesterson J, Olawaiye AB, Moxley K, Waggoner S, Santin A, Rader JS, Kizer NT, Thaker PH, Powell MA, Mutch DG, Birrer MJ, Goodfellow PJ.

Gynecol Oncol. 2019 May;153(2):335-342. doi: 10.1016/j.ygyno.2019.02.028. Epub 2019 Feb 28.

11.

Continuous epidural infusion in gynecologic oncology patients undergoing exploratory laparotomy: The new standard for decreased postoperative pain and opioid use.

Huepenbecker SP, Cusworth SE, Kuroki LM, Lu P, Samen CDK, Woolfolk C, Deterding R, Wan L, Helsten DL, Bottros M, Mutch DG, Powell MA, Massad LS, Thaker PH.

Gynecol Oncol. 2019 May;153(2):356-361. doi: 10.1016/j.ygyno.2019.02.017. Epub 2019 Feb 22.

PMID:
30798950
12.

Inpatient management of hypercalcemia portends a poor prognosis among gynecologic oncology patients: A trigger to initiate hospice care?

Cripe JC, Buchanan TR Jr, Wan L, Hagemann AR, McCourt CK, Massad LS, Fuh KC, Mutch DG, Powell MA, Thaker PH, Kuroki LM.

Gynecol Oncol Rep. 2019 Jan 26;28:1-5. doi: 10.1016/j.gore.2019.01.005. eCollection 2019 May.

13.

Endometrial Tumor Immune Response: Predictive Biomarker of Response to Immunotherapy.

Mullen MM, Mutch DG.

Clin Cancer Res. 2019 Apr 15;25(8):2366-2368. doi: 10.1158/1078-0432.CCR-18-4122. Epub 2019 Jan 28.

PMID:
30692101
14.

Association between body mass index and surgical menopausal symptoms in patients with early stage endometrial cancer.

Cripe JC, Buchanan TR Jr, Kuroki LM, Wan L, Mills KA, Massad L, Hagemann AR, Fuh KC, Mutch DG, Powell MA, Matsuo K, Thaker PH.

Gynecol Oncol. 2019 Apr;153(1):123-126. doi: 10.1016/j.ygyno.2019.01.009. Epub 2019 Jan 14.

PMID:
30651188
15.

Nomogram for Predicting Individual Survival After Recurrence of Advanced-Stage, High-Grade Ovarian Carcinoma.

Rose PG, Java JJ, Salani R, Geller MA, Secord AA, Tewari KS, Bender DP, Mutch DG, Friedlander ML, Van Le L, Method MW, Hamilton CA, Lee RB, Wenham RM, Guntupalli SR, Markman M, Muggia FM, Armstrong DK, Bookman MA, Burger RA, Copeland LJ.

Obstet Gynecol. 2019 Feb;133(2):245-254. doi: 10.1097/AOG.0000000000003086. Erratum in: Obstet Gynecol. 2019 Apr;133(4):830.

PMID:
30633128
16.

Postpartum salpingectomy: a procedure whose time has come.

Zamorano AS, Mutch DG.

Am J Obstet Gynecol. 2019 Jan;220(1):8-9. doi: 10.1016/j.ajog.2018.09.041. No abstract available.

PMID:
30591122
17.

A randomized phase II study of cabozantinib versus weekly paclitaxel in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study.

Matulonis UA, Sill MW, Makker V, Mutch DG, Carlson JW, Darus CJ, Mannel RS, Bender DP, Crane EK, Aghajanian C.

Gynecol Oncol. 2019 Mar;152(3):548-553. doi: 10.1016/j.ygyno.2018.12.008. Epub 2018 Dec 23.

PMID:
30587441
18.

Obesity counseling in obstetrics and gynecology: provider perceptions and barriers.

Huepenbecker SP, Wan L, Leon A, Rosen D, Hoff J, Kuroki LM, Fuh KC, Powell MA, Mutch DG, Colditz GA, Hagemann AR.

Gynecol Oncol Rep. 2018 Dec 10;27:31-34. doi: 10.1016/j.gore.2018.12.001. eCollection 2019 Feb. French.

19.

Therapeutic Inhibition of the Receptor Tyrosine Kinase AXL Improves Sensitivity to Platinum and Taxane in Ovarian Cancer.

Quinn JM, Greenwade MM, Palisoul ML, Opara G, Massad K, Guo L, Zhao P, Beck-Noia H, Hagemann IS, Hagemann AR, McCourt CK, Thaker PH, Powell MA, Mutch DG, Fuh KC.

Mol Cancer Ther. 2019 Feb;18(2):389-398. doi: 10.1158/1535-7163.MCT-18-0537. Epub 2018 Nov 26.

PMID:
30478151
20.

Intensity Modulated Radiation Therapy and Image-Guided Adapted Brachytherapy for Cervix Cancer.

Lin AJ, Kidd E, Dehdashti F, Siegel BA, Mutic S, Thaker PH, Massad LS, Powell MA, Mutch DG, Markovina S, Schwarz J, Grigsby PW.

Int J Radiat Oncol Biol Phys. 2019 Apr 1;103(5):1088-1097. doi: 10.1016/j.ijrobp.2018.11.012. Epub 2018 Nov 14.

PMID:
30445171
21.

Adipokines Deregulate Cellular Communication via Epigenetic Repression of Gap Junction Loci in Obese Endometrial Cancer.

Polusani SR, Huang YW, Huang G, Chen CW, Wang CM, Lin LL, Osmulski P, Lucio ND, Liu L, Hsu YT, Zhou Y, Lin CL, Aguilera-Barrantes I, Valente PT, Kost ER, Chen CL, Shim EY, Lee SE, Ruan J, Gaczynska ME, Yan P, Goodfellow PJ, Mutch DG, Jin VX, Nicholson BJ, Huang TH, Kirma NB.

Cancer Res. 2019 Jan 1;79(1):196-208. doi: 10.1158/0008-5472.CAN-18-1615. Epub 2018 Nov 2.

PMID:
30389702
22.

Corrigendum to "Does adjuvant chemotherapy dose modification have an impact on the outcome of patients diagnosed with advanced stage ovarian cancer? An NRG Oncology/Gynecologic Oncology Group study" [Gynecol. Oncol. 151 (2018) 18-23].

Olawaiye AB, Java JJ, Krivak TC, Friedlander M, Mutch DG, Glaser G, Geller M, O'Malley DM, Wenham RM, Lee RB, Bodurka DC, Herzog TJ, Bookman MA.

Gynecol Oncol. 2019 Jan;152(1):220. doi: 10.1016/j.ygyno.2018.10.022. Epub 2018 Oct 23. No abstract available.

23.

Pathology of cancers of the female genital tract including molecular pathology.

Prat J, Mutch DG.

Int J Gynaecol Obstet. 2018 Oct;143 Suppl 2:93-108. doi: 10.1002/ijgo.12617.

PMID:
30306579
24.

Evaluation of Ovarian Cancer: Initial Application of Coregistered Photoacoustic Tomography and US.

Nandy S, Mostafa A, Hagemann IS, Powell MA, Amidi E, Robinson K, Mutch DG, Siegel C, Zhu Q.

Radiology. 2018 Dec;289(3):740-747. doi: 10.1148/radiol.2018180666. Epub 2018 Sep 11.

PMID:
30204078
25.

SQ1274, a novel microtubule inhibitor, inhibits ovarian and uterine cancer cell growth.

Mills KA, Roach ST, Quinn JM, Guo L, Beck HM, Lomonosova E, Ilivicky AR, Starks CM, Lawrence JA, Hagemann AR, McCourt C, Thaker PH, Powell MA, Mutch DG, Fuh KC.

Gynecol Oncol. 2018 Nov;151(2):337-344. doi: 10.1016/j.ygyno.2018.08.008. Epub 2018 Sep 3.

26.

Does adjuvant chemotherapy dose modification have an impact on the outcome of patients diagnosed with advanced stage ovarian cancer? An NRG Oncology/Gynecologic Oncology Group study.

Olawaiye AB, Java JJ, Krivak TC, Friedlander M, Mutch DG, Glaser G, Geller M, O'Malley DM, Wenham RM, Lee RB, Bodurka DC, Herzog TJ, Bookman MA.

Gynecol Oncol. 2018 Oct;151(1):18-23. doi: 10.1016/j.ygyno.2018.07.021. Epub 2018 Aug 19. Erratum in: Gynecol Oncol. 2018 Oct 22;:.

PMID:
30135020
27.

Gynecologic Oncologists' Perceptions of Palliative Care and Associated Barriers: A Survey of the Society of Gynecologic Oncology.

Cripe JC, Mills KA, Kuroki LK, Wan L, Hagemann AR, Fuh KC, Mutch DG, Powell MA, Thaker PH.

Gynecol Obstet Invest. 2019;84(1):50-55. doi: 10.1159/000491089. Epub 2018 Aug 10. Review.

PMID:
30099446
28.

Receipt of adjuvant endometrial cancer treatment according to race: an NRG Oncology/Gynecologic Oncology Group 210 Study.

Felix AS, Cohn DE, Brasky TM, Zaino R, Park K, Mutch DG, Creasman WT, Thaker PH, Walker JL, Moore RG, Lele SB, Guntupalli SR, Downs LS, Nagel CI, Boggess JF, Pearl ML, Ioffe OB, Randall ME, Brinton LA.

Am J Obstet Gynecol. 2018 Nov;219(5):459.e1-459.e11. doi: 10.1016/j.ajog.2018.08.002. Epub 2018 Aug 7.

PMID:
30096321
29.

Lymphnode staging update in the American Joint Committee on Cancer 8th Edition cancer staging manual.

Olawaiye AB, Mutch DG.

Gynecol Oncol. 2018 Jul;150(1):7-8. doi: 10.1016/j.ygyno.2018.02.021. Epub 2018 Mar 12. No abstract available.

PMID:
29540290
30.

Adenovirus platform enhances transduction efficiency of human mesenchymal stem cells: An opportunity for cellular carriers of targeted TRAIL-based TR3 biologics in ovarian cancer.

Kuroki LM, Jin X, Dmitriev IP, Kashentseva EA, Powell MA, Mutch DG, Dietz AB, Curiel DT, Hawkins WG, Spitzer D.

PLoS One. 2017 Dec 21;12(12):e0190125. doi: 10.1371/journal.pone.0190125. eCollection 2017.

31.

Clinicopathologic characteristics associated with long-term survival in advanced epithelial ovarian cancer: an NRG Oncology/Gynecologic Oncology Group ancillary data study.

Hamilton CA, Miller A, Casablanca Y, Horowitz NS, Rungruang B, Krivak TC, Richard SD, Rodriguez N, Birrer MJ, Backes FJ, Geller MA, Quinn M, Goodheart MJ, Mutch DG, Kavanagh JJ, Maxwell GL, Bookman MA.

Gynecol Oncol. 2018 Feb;148(2):275-280. doi: 10.1016/j.ygyno.2017.11.018. Epub 2017 Nov 28.

32.

Predictive modeling for determination of microscopic residual disease at primary cytoreduction: An NRG Oncology/Gynecologic Oncology Group 182 Study.

Horowitz NS, Larry Maxwell G, Miller A, Hamilton CA, Rungruang B, Rodriguez N, Richard SD, Krivak TC, Fowler JM, Mutch DG, Van Le L, Lee RB, Argenta P, Bender D, Tewari KS, Gershenson D, Java JJ, Bookman MA.

Gynecol Oncol. 2018 Jan;148(1):49-55. doi: 10.1016/j.ygyno.2017.10.011. Epub 2017 Nov 23.

33.

MAX Mutations in Endometrial Cancer: Clinicopathologic Associations and Recurrent MAX p.His28Arg Functional Characterization.

Walker CJ, Rush CM, Dama P, O'Hern MJ, Cosgrove CM, Gillespie JL, Zingarelli RA, Smith B, Stein ME, Mutch DG, Shakya R, Chang CW, Selvendiran K, Song JW, Cohn DE, Goodfellow PJ.

J Natl Cancer Inst. 2018 May 1;110(5):517-526. doi: 10.1093/jnci/djx238.

34.

Moving forward with actionable therapeutic targets and opportunities in endometrial cancer: NCI clinical trials planning meeting report on identifying key genes and molecular pathways for targeted endometrial cancer trials.

MacKay HJ, Levine DA, Bae-Jump VL, Bell DW, McAlpine JN, Santin A, Fleming GF, Mutch DG, Nephew KP, Wentzensen N, Goodfellow PJ, Dorigo O, Nijman HW, Broaddus R, Kohn EC.

Oncotarget. 2017 Aug 3;8(48):84579-84594. doi: 10.18632/oncotarget.19961. eCollection 2017 Oct 13. Review.

35.

An NRG Oncology/GOG study of molecular classification for risk prediction in endometrioid endometrial cancer.

Cosgrove CM, Tritchler DL, Cohn DE, Mutch DG, Rush CM, Lankes HA, Creasman WT, Miller DS, Ramirez NC, Geller MA, Powell MA, Backes FJ, Landrum LM, Timmers C, Suarez AA, Zaino RJ, Pearl ML, DiSilvestro PA, Lele SB, Goodfellow PJ.

Gynecol Oncol. 2018 Jan;148(1):174-180. doi: 10.1016/j.ygyno.2017.10.037. Epub 2017 Nov 11.

36.

Endometrial carcinoma recurrence according to race and ethnicity: An NRG Oncology/Gynecologic Oncology Group 210 Study.

Felix AS, Brasky TM, Cohn DE, Mutch DG, Creasman WT, Thaker PH, Walker JL, Moore RG, Lele SB, Guntupalli SR, Downs LS, Nagel C, Boggess JF, Pearl ML, Ioffe OB, Deng W, Miller DS, Brinton LA.

Int J Cancer. 2018 Mar 15;142(6):1102-1115. doi: 10.1002/ijc.31127. Epub 2017 Nov 6.

37.

Novel SOX17 frameshift mutations in endometrial cancer are functionally distinct from recurrent missense mutations.

Walker CJ, O'Hern MJ, Serna VA, Kurita T, Miranda MA, Sapp CE, Mutch DG, Cohn DE, Goodfellow PJ.

Oncotarget. 2017 Aug 12;8(40):68758-68768. doi: 10.18632/oncotarget.20213. eCollection 2017 Sep 15.

38.

Clear Cell Carcinoma of the Endometrium: Evaluation of Prognostic Parameters in a Multi-institutional Cohort of 165 Cases.

Abdulfatah E, Sakr S, Thomas S, Al-Wahab Z, Mutch DG, Dowdy S, Bandyopadhyay S, Munkarah A, Elshaikh M, Morris R, Ali-Fehmi R.

Int J Gynecol Cancer. 2017 Oct;27(8):1714-1721. doi: 10.1097/IGC.0000000000001050.

39.

The FOXA2 transcription factor is frequently somatically mutated in uterine carcinosarcomas and carcinomas.

Le Gallo M, Rudd ML, Urick ME, Hansen NF; National Institutes of Health Intramural Sequencing Center Comparative Sequencing Program, Merino MJ, Mutch DG, Goodfellow PJ, Mullikin JC, Bell DW.

Cancer. 2018 Jan 1;124(1):65-73. doi: 10.1002/cncr.30971. Epub 2017 Sep 21.

40.

Two sisters with Mayer-Rokitansky-Küster-Hauser syndrome and serous adenocarcinoma of the ovary.

Huepenbecker SP, Divine L, Chu CS, Mutch DG.

Gynecol Oncol Rep. 2017 Sep 7;22:13-15. doi: 10.1016/j.gore.2017.09.002. eCollection 2017 Nov.

41.

Benefit of combination chemotherapy and radiation stratified by grade of stage IIIC endometrial cancer.

Binder PS, Kuroki LM, Zhao P, Cusworth S, Divine LM, Hagemann AR, McCourt CK, Thaker PH, Powell MA, Mutch DG, Massad LS.

Gynecol Oncol. 2017 Nov;147(2):309-314. doi: 10.1016/j.ygyno.2017.08.031. Epub 2017 Sep 13.

PMID:
28916118
42.

Inhibition of the Receptor Tyrosine Kinase AXL Restores Paclitaxel Chemosensitivity in Uterine Serous Cancer.

Palisoul ML, Quinn JM, Schepers E, Hagemann IS, Guo L, Reger K, Hagemann AR, McCourt CK, Thaker PH, Powell MA, Mutch DG, Fuh KC.

Mol Cancer Ther. 2017 Dec;16(12):2881-2891. doi: 10.1158/1535-7163.MCT-17-0587. Epub 2017 Sep 13.

43.

An evaluation of progression free survival and overall survival of ovarian cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum therapy: An NRG Oncology/Gynecologic Oncology Group experience.

Oliver KE, Brady WE, Birrer M, Gershenson DM, Fleming G, Copeland LJ, Tewari K, Argenta PA, Mannel RS, Secord AA, Stephan JM, Mutch DG, Stehman FB, Muggia FM, Rose PG, Armstrong DK, Bookman MA, Burger RA, Farley JH.

Gynecol Oncol. 2017 Nov;147(2):243-249. doi: 10.1016/j.ygyno.2017.08.004. Epub 2017 Aug 12.

44.

Opposing effects of cancer-type-specific SPOP mutants on BET protein degradation and sensitivity to BET inhibitors.

Janouskova H, El Tekle G, Bellini E, Udeshi ND, Rinaldi A, Ulbricht A, Bernasocchi T, Civenni G, Losa M, Svinkina T, Bielski CM, Kryukov GV, Cascione L, Napoli S, Enchev RI, Mutch DG, Carney ME, Berchuck A, Winterhoff BJN, Broaddus RR, Schraml P, Moch H, Bertoni F, Catapano CV, Peter M, Carr SA, Garraway LA, Wild PJ, Theurillat JP.

Nat Med. 2017 Sep;23(9):1046-1054. doi: 10.1038/nm.4372. Epub 2017 Aug 14.

45.

A Transperineal Approach to Hysterectomy of a Retained Didelphic Uterine Horn.

Mullen MM, Kuroki LM, Hunt SR, Ratkowski KL, Mutch DG.

Obstet Gynecol. 2017 Sep;130(3):561-564. doi: 10.1097/AOG.0000000000002196.

PMID:
28796686
46.

The effect of a multidisciplinary palliative care initiative on end of life care in gynecologic oncology patients.

Mullen MM, Divine LM, Porcelli BP, Wilkinson-Ryan I, Dans MC, Powell MA, Mutch DG, Hagemann AR, Thaker PH.

Gynecol Oncol. 2017 Nov;147(2):460-464. doi: 10.1016/j.ygyno.2017.08.002. Epub 2017 Aug 4.

PMID:
28784245
47.

Intensity modulated radiation therapy for squamous cell carcinoma of the vulva: Treatment technique and outcomes.

Rao YJ, Chundury A, Schwarz JK, Hassanzadeh C, DeWees T, Mullen D, Powell MA, Mutch DG, Grigsby PW.

Adv Radiat Oncol. 2017 Feb 28;2(2):148-158. doi: 10.1016/j.adro.2017.02.006. eCollection 2017 Apr-Jun.

48.

Improved survival with definitive chemoradiation compared to definitive radiation alone in squamous cell carcinoma of the vulva: A review of the National Cancer Database.

Rao YJ, Chin RI, Hui C, Mutch DG, Powell MA, Schwarz JK, Grigsby PW, Markovina S.

Gynecol Oncol. 2017 Sep;146(3):572-579. doi: 10.1016/j.ygyno.2017.06.022. Epub 2017 Jun 27.

PMID:
28662775
49.

Wound Complication Rates After Staples or Suture for Midline Vertical Skin Closure in Obese Women: A Randomized Controlled Trial.

Kuroki LM, Mullen MM, Massad LS, Wu N, Liu J, Mutch DG, Powell MA, Hagemann AR, Thaker PH, McCourt CK, Novetsky AP.

Obstet Gynecol. 2017 Jul;130(1):91-99. doi: 10.1097/AOG.0000000000002061.

50.

Unethical randomised controlled trial of cervical screening in India: US Freedom of Information Act disclosures.

Suba EJ, Ortega RE, Mutch DG.

BMJ Glob Health. 2017 Apr 26;2(2):e000177. doi: 10.1136/bmjgh-2016-000177. eCollection 2017. Retraction in: BMJ Glob Health. 2017 May 18;2(2):.

PMID:
28589014

Supplemental Content

Loading ...
Support Center